Incyte Pays US$900 M Upfront to Partner with MorphoSys for Tafasitamab
By Michelle Liu
Pharma Deals Review: Vol 2020 Issue 1 (Table of Contents)
Published: 21 Jan-2020
DOI: 10.3833/pdr.v2020.i1.2500 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a bid to reduce its reliance on Jakafi® (ruxolitinib), Incyte has agreed to partner with MorphoSys to develop and commercialise its anti-CD19 antibody, tafasitamab, globally...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS